These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20200515)

  • 1. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases.
    Arrese M; Karpen SJ
    Clin Pharmacol Ther; 2010 Apr; 87(4):473-8. PubMed ID: 20200515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?
    Rudraiah S; Zhang X; Wang L
    Annu Rev Pharmacol Toxicol; 2016; 56():605-626. PubMed ID: 26738480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic targets for cholestatic and fatty liver disease.
    Trauner M; Fuchs CD
    Gut; 2022 Jan; 71(1):194-209. PubMed ID: 34615727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear receptors in acute and chronic cholestasis.
    Gonzalez-Sanchez E; Firrincieli D; Housset C; Chignard N
    Dig Dis; 2015; 33(3):357-66. PubMed ID: 26045270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
    Fuchs CD; Traussnigg SA; Trauner M
    Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile.
    Moya M; Gómez-Lechón MJ; Castell JV; Jover R
    Chem Biol Interact; 2010 Mar; 184(3):376-87. PubMed ID: 20079722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear receptors in liver disease.
    Wagner M; Zollner G; Trauner M
    Hepatology; 2011 Mar; 53(3):1023-34. PubMed ID: 21319202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesoid X receptor modulators (2011 - 2014): a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.
    Mulder J; Karpen SJ; Tietge UJ; Kuipers F
    Front Biosci (Landmark Ed); 2009 Jan; 14(7):2599-630. PubMed ID: 19273222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Look who's talking: nuclear receptors in the liver and gastrointestinal tract.
    Downes M; Liddle C
    Cell Metab; 2008 Mar; 7(3):195-9. PubMed ID: 18316024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets.
    George J; Liddle C
    Mol Pharm; 2008; 5(1):49-59. PubMed ID: 18072723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Let there be bile"--understanding hepatic injury in cholestasis.
    Sokol RJ; Devereaux M; Dahl R; Gumpricht E
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S4-9. PubMed ID: 16819400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways.
    Mellor CL; Steinmetz FP; Cronin MT
    Crit Rev Toxicol; 2016 Feb; 46(2):138-52. PubMed ID: 26451809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity.
    Zollner G; Wagner M; Trauner M
    Pharmacol Ther; 2010 Jun; 126(3):228-43. PubMed ID: 20388526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptin: the prototypic adipocytokine and its role in NAFLD.
    Procaccini C; Galgani M; De Rosa V; Carbone F; La Rocca C; Ranucci G; Iorio R; Matarese G
    Curr Pharm Des; 2010 Jun; 16(17):1902-12. PubMed ID: 20370676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Essential role of nuclear receptors for the evaluation of the benefits of bioactive herbal extracts on liver function.
    Wang F; Wu Y; Xie X; Sun J; Chen W
    Biomed Pharmacother; 2018 Mar; 99():798-809. PubMed ID: 29710478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury.
    Stedman CA; Liddle C; Coulter SA; Sonoda J; Alvarez JG; Moore DD; Evans RM; Downes M
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2063-8. PubMed ID: 15684063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors.
    Marschall HU; Wagner M; Zollner G; Trauner M
    Mol Pharm; 2007; 4(6):895-910. PubMed ID: 18001054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease.
    Musso G; Gambino R; Cassader M
    Annu Rev Med; 2010; 61():375-92. PubMed ID: 20059344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.